What is Lunit?
Lunit is at the forefront of revolutionizing healthcare through artificial intelligence, aiming to establish data-driven medicine as the universal standard of care. The company specializes in developing sophisticated AI solutions tailored for precision diagnostics and therapeutics, with a particular focus on combating cancer. By leveraging advanced AI, Lunit seeks to provide accurate diagnoses at optimal costs and identify the most effective treatment pathways for individual patients, thereby enhancing patient outcomes and streamlining healthcare delivery.
How much funding has Lunit raised?
Lunit has raised a total of $307.5M across 5 funding rounds:
Series A
$3.5M
Series B
$15M
Series C
$78M
Other Financing Round
$61M
Other Financing Round
$150M
Series A (2016): $3.5M, investors not publicly disclosed
Series B (2018): $15M led by Capital Intervest, Mirae Asset Global Investments, KT, Legend Capital, SOFTBANK Korea Co., and Kakao Ventures
Series C (2021): $78M supported by Legend Capital, Kakao Ventures, Guardant Health, Shinhan Investment, IMM Investment, and InterVest
Other Financing Round (2021): $61M featuring HealthQuest Capital, BrightEdge, and Casdin Capital
Other Financing Round (2023): $150M, investors not publicly disclosed
Key Investors in Lunit
Legend Capital
Legend Capital is a private equity fund manager focused on innovation and growth enterprises, managing significant USD and RMB funds with a strong presence in China.
Kakao Ventures
Kakao Ventures is an investment firm that supports innovative companies, likely focusing on technology and digital solutions, aligning with Lunit's AI-driven approach.
Guardant Health
Guardant Health provides cancer diagnostics and testing services, making it a strategic investor with deep expertise in the oncology space where Lunit also operates.
What's next for Lunit?
With the recent influx of major enterprise-level funding and a significant strategic investment, Lunit is poised to accelerate its research and development initiatives and expand its market reach. This capital infusion will likely fuel the enhancement of its AI diagnostic and therapeutic platforms, potentially leading to broader clinical adoption and strategic partnerships. The company's trajectory suggests a continued focus on innovation in oncology and precision medicine, aiming to solidify its position as a leader in AI-powered healthcare solutions.
See full Lunit company page
